Design and construction of multi epitope- peptide vaccine candidate for rabies virus

• Published in: Bioinformation Vol. 19; no. 2; pp. 167 - 177
• Main Authors: Abdulhameed Odhar, Hasanain, Hashim, Ahmed Fadhil, Humadi, Suhad Sami, Ahjel, Salam Waheed
• Format: Journal Article
• Language: English
• Published: Singapore Biomedical Informatics 28.02.2023
• Subjects: Antibodies; Antigens; Bats; Encephalitis; Epitope mapping; Glycoproteins; Immune response; Immune system; Informatics; Lymphocytes B; Lymphocytes T; Lyssavirus; Molecular docking; Peptides; Rabies; Vaccines; Viruses; docking; rabies; glycoprotein; dynamics simulation; epitope; peptide vaccine
• ISSN: 0973-2063; 0973-8894; 0973-2063
• DOI: 10.6026/97320630019167

Rabies virus is a zoonotic pathogen that causes lethal encephalitis with a case fatality rate of almost 100% in unvaccinated individuals. The currently available vaccines against rabies are composed of inactivated viral particles that only confer a short-term immune response. It is well-known that the entry of rabies virus into host cells is mediated by a trimeric glycoprotein presents on the surface of viral envelope. As the sole viral surface protein, this trimeric glycoprotein represents a promising molecular target to design new vaccines and neutralizing antibodies against rabies virus. Epitope mapping studies had identified several antigenic sites on the surface of trimeric pre-fusion glycoprotein of rabies virus. Therefore, it is of interest to screen the rabies virus glycoprotein by different web-based immuno-informatics tools to identify potential B-cells and T-cells linear epitopes. Here, we present a construct of peptide vaccine that consists of these predicted linear epitopes of rabies virus glycoprotein together with appropriate linkers and adjuvant. Various online prediction tools, molecular docking and dynamics simulation assume that the vaccine construct may be stable, safe and effective. However, validation of these in-silico results is necessary both in vitro and in vivo setting.